EMCURE PHARMACEUTICALS L Share Price

EMCURE PHARMACEUTICALS L Share Price

NSE: EMCURE
|
Pharmaceuticals
₹ 1,883.00
+₹13.50 (0.72%)
1D
Last updated 24 Jul, 2026, 15:29 IST

EMCURE PHARMACEUTICALS L Share Price Today

As of 25 Jul 2026, EMCURE PHARMACEUTICALS L share price is ₹1,883.00. The stock opened at ₹1,864.20, compared to its previous close of ₹1,869.50. During today's trading session, EMCURE PHARMACEUTICALS L share price moved in the range of ₹1,855.40 to ₹1,892.00, with an average price of ₹1,873.70 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,260.00 and a high of ₹1,944.00. On the performance front, EMCURE PHARMACEUTICALS L share price has increased by 22.88% over the last six months and is up 31.96% on a year-on-year basis.

₹1,855.40
0.72% up today
₹1,892.00
1D LOW
1D HIGH

EMCURE PHARMACEUTICALS L Returns Calculator

Circuit
L
H
₹1,692.90
₹2,069.10
52-week
L
H
₹1,260.00
₹1,944.00
Mkt Cap Cr
35,357.30
P/E
37.92
P/B
7.21
ROE
18.67%
D/E
0.43
ROCE
21.76%
Div. Yield
0.19%
EPS(TTM)
38.67
Turnover
1.13
EV/EBITDA
19.98
Net Margin
0.00%
Op. Margin
0.00%
ROA
9.79%
Quick Ratio
0.00
Curr. Ratio
1.98
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Emcure Pharma outperforming all market indices
Step 3 of 5
Valuation
Fairly Valued
Emcure Pharma appears to be fairly valued compared to its peers
Step 5 of 5
Earnings
Excellent
Emcure Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,65,711.0036.735.0514.85%0.5518.72%18.850.91%0.5610.90
Divis Laboratories1,93,860.0061.369.4016.19%0.0021.00%9.430.50%0.5898.19
Torrent Pharmaceuticals1,92,687.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,12,593.0033.553.2711.27%0.0014.95%423.360.92%0.4543.52
Zydus Lifesciences1,11,082.0017.393.2319.69%0.3520.30%3.700.11%0.3935.38
Lupin1,09,553.0019.834.7127.01%0.0327.44%3.510.78%0.61129.18
Mankind Pharma1,03,472.001.050.1212.65%0.4212.97%5.050.05%0.5449.37
Dr. Reddy's Laboratories96,204.7030.222.5311.07%0.1812.54%377.960.69%0.4138.68
Aurobindo Pharma88,508.4025.272.349.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs84,727.3060.2610.1018.21%0.4016.70%97.210.12%0.6413.72

EMCURE PHARMACEUTICALS L Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹7,896.00₹6,658.25₹5,985.81₹5,855.39
Other Income₹72.79₹56.99₹45.91₹63.47
Total Revenue₹7,968.78₹6,715.24₹6,031.72₹5,918.86
Total Expenses₹6,987.06₹5,978.08₹5,278.36₹4,946.31
Profit Before Tax₹971.35₹727.23₹747.22₹972.55
Tax₹263.88₹199.65₹185.37₹269.99
Profit After Tax₹707.47₹527.58₹561.85₹702.56
EPS - Basic₹36.43₹27.54₹29.42₹36.62
EPS - Diluted₹36.43₹27.54₹29.42₹36.62

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹971.35₹727.23₹747.22₹972.55
Income before WC changes₹1,522.86₹1,270.38₹1,239.56₹1,371.29
Change in Assets-₹599.85-₹166.98-₹277.81-₹603.40
Change in Liabilities₹175.56₹217.49-₹14.42₹311.49
Change in WC-₹424.30₹50.52-₹292.24-₹291.91
Cash flow from Operations₹851.71₹1,097.24₹746.85₹768.21
Cash flow from Investing-₹94.00-₹712.51-₹467.69-₹788.79
Cash flow from Financing-₹813.96-₹164.21-₹145.40-₹151.85
Total Cash Flow-₹56.25₹220.52₹133.77-₹172.44
Cash (Start of the year)₹43.99-₹174.53-₹308.17-₹350.04
Cash (End of the year)-₹14.31₹43.99-₹174.53-₹308.17

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹3,676.86₹3,546.25₹2,836.62₹2,639.37
Current Assets₹4,555.86₹4,259.92₹3,835.91₹3,424.10
Total Assets₹8,232.72₹7,806.16₹6,672.53₹6,063.47
Current Liabilities₹2,668.27₹3,210.47₹3,019.19₹2,964.83
Net Current Asset₹1,887.59₹1,049.44₹816.72₹459.27
Non-Current Liabilities₹922.90₹1,473.93₹1,003.68₹984.50
Equity Capital₹4,641.55₹3,121.77₹2,649.66₹2,114.14
Total Equity & Liabilities₹8,232.72₹7,806.16₹6,672.53₹6,063.47

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹4,381.92₹3,497.66₹3,107.09₹3,387.24
Other Income₹142.48₹138.26₹125.35₹132.68
Total Revenue₹4,524.40₹3,635.91₹3,232.44₹3,519.92
Total Expenses₹4,096.69₹3,426.69₹3,013.95₹2,903.50
Profit Before Tax₹427.71₹199.91₹212.34₹616.42
Tax₹110.58₹39.08₹52.28₹169.61
Profit After Tax₹317.13₹160.83₹160.06₹446.81
EPS - Basic₹16.95₹8.89₹8.85₹24.71
EPS - Diluted₹16.95₹8.89₹8.85₹24.71

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹427.71₹199.91₹212.34₹616.42
Income before WC changes₹711.85₹525.47₹521.55₹881.42
Change in Assets-₹368.39-₹91.66-₹22.13-₹324.96
Change in Liabilities₹280.94₹218.02₹90.49₹41.92
Change in WC-₹87.45₹126.36₹68.37-₹283.04
Cash flow from Operations₹558.29₹584.97₹505.37₹427.71
Cash flow from Investing-₹435.61-₹171.08-₹270.44-₹189.00
Cash flow from Financing-₹49.25-₹287.75-₹54.52-₹342.96
Total Cash Flow₹73.43₹126.15₹180.42-₹309.06
Cash (Start of the year)-₹88.91-₹213.05-₹393.35-₹84.29
Cash (End of the year)-₹17.53-₹88.91-₹213.05-₹393.35

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹2,956.06₹2,633.50₹2,456.44₹2,181.56
Current Assets₹2,460.05₹2,123.43₹2,159.41₹2,141.63
Total Assets₹5,416.11₹4,756.93₹4,615.85₹4,323.18
Current Liabilities₹1,719.16₹2,130.12₹1,996.33₹1,934.06
Net Current Asset₹740.89-₹6.68₹163.07₹207.56
Non-Current Liabilities₹672.59₹691.72₹777.65₹676.59
Equity Capital₹3,024.36₹1,935.10₹1,841.87₹1,712.53
Total Equity & Liabilities₹5,416.11₹4,756.93₹4,615.85₹4,323.18
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1881
2
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 2
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
57.82
Neutral
ATR (14)
54.97
Neutral
STOCH(9,6)
62.7
Neutral
STOCH RSI (14)
49.81
Neutral
ADX(9)
25.64
Bearish
UO(9)
48.6
Neutral
ROC(12)
1.41
Bullish
WillR(14)
-37.3
Neutral
Period
Simple value
Exponential vaue
5D
1865.52
1866.84
10D
1833.84
1849.14
20D
1836.39
1828.69
50D
1771.79
1773.35
100D
1671.52
1694.24

About EMCURE PHARMACEUTICALS L

EMCURE PHARMACEUTICALS L Share Price
ISIN
INE168P01015
Sector Market Cap
₹ 35,357.3 Cr

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.

EMCURE PHARMACEUTICALS L Financial Highlights

  • Revenue: EMCURE PHARMACEUTICALS L reported revenue of ₹9,216.20 crore in FY26 vs ₹7,963.26 crore in FY25. It showed an increase of 15.73% on a yearly basis.
  • Operating Profit: EMCURE PHARMACEUTICALS L reported an operating profit of ₹1,287.14 crore in FY26 vs ₹971.35 crore in FY25. It showed an increase of 32.51% on a year-on-year basis.
  • Net Profit: EMCURE PHARMACEUTICALS L reported a net profit of ₹941.27 crore in FY26 vs ₹707.47 crore in FY25. It showed an increase of 33.05% on a yearly basis.

EMCURE PHARMACEUTICALS L Quarterly Result Highlights

  • EMCURE PHARMACEUTICALS L reported revenue of ₹2,473.69 crore in Mar 2026, compared with ₹2,365.33 crore in Dec 2025, representing an increase of 4.58% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported an operating profit of ₹341.18 crore in Mar 2026, compared with ₹313.79 crore in Dec 2025, representing an increase of 8.73% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported a profit of ₹243.74 crore in Mar 2026, compared with ₹231.37 crore in Dec 2025, reflecting an increase of 5.35% on a QoQ basis.
  • The earnings per share (EPS) of EMCURE PHARMACEUTICALS L stood at ₹36.43 during Mar 2026.
Know more
Promoters
77.83%
FII
4.88%
Other DII
1.60%
Retail and other
8.83%
Mutual funds
6.87%
Foreign institutions - FII
Compare against other stocks
EMCURE PHARMACEUTICALS L Share Price
EMCURE PHARMACEUTICALS L
Pharmaceuticals
Add Stock
Add Another

FAQs on EMCURE PHARMACEUTICALS L Share Price